Society of Nuclear Medicine & Molecular Imaging Annual Meeting (SNMMI)

Use of PET-guided radiotherapy may enable the opportunity to incorporate biological information into the planning and delivery of radiation.

The use of 68Ga-Pentixafor compliments fluorodeoxyglucose and had no correlation with CXCR4 immunohistochemistry.

A retrospective study shows that [177Lu]Lu-PSMA-617 retreatment led to a median OS of 14.5 months in castration-resistant prostate cancer.

Treatment with 177Lu-PSMA-617 resulted in poor outcomes for patients with metastatic castration-resistant prostate cancer whose tumors had little to no prostate-specific membrane antigen expression.

Patients with gastrointestinal stromal tumors may benefit from 68GA-RM26 PET/CT vs 18F-FDG, according to findings presented at the 2022 Society of Nuclear Medicine & Molecular Imaging Annual Meeting.

Independent factors such as the integrated clinical radiomics model and 18F-FDG PET/CT radiomics signature may be predictive of progression-free survival in breast cancer.

Data from the SPOTLIGHT trial indicate agreement among trained PET readers was highly concordant with use of 18F-rhPSMA-7.3 imaging for recurrent prostate cancer.